Meet the current Society board

Executive Positions

Judi Wardwell-Swanson
Judi Wardwell-SwansonPresident

Judi is a Sr. Application Scientist at InSphero, Inc. where she assists Pharma, Biotech and Academic scientists integrate multicellular 3D models derived from human donor tissues into their drug discovery workflow. In addition to her role as InSphero’s Senior Application Scientist, she also serves as the lead scientist for their high content imaging strategy and technical advisor for their newly acquired imaging platform. Judi has been an active member of SBI2 for 5 years, serving as a Councilor on the Board of Directors from 2016-2019 and then as President Elect.

Sr. Application Scientist
InSphero, Inc.
Brunswick, ME

Debra Nickischer
Debra NickischerSecretary

Debby was elected Secretary Elect of SBI2 in 2019 and moved to Secretary in 2020. Debby has been heavily involved in the board and society for many years. She is currently a Research Scientist at Arvinas using her 20 years of high content imaging experience to help with Lead Discovery efforts.

Research Scientist
Arvinas
New Haven, CT

Jeff Haskins
Jeff HaskinsTreasurer

Jeff is currently an Executive Director of Global In Vitro Toxicology at Charles River Laboratories. He has over 30 years experience in cellular imaging and toxicology. Jeff was previously a senior research associate at Pfizer in the Discovery Toxicology Group and R&D Director at Thermo Fisher Scientific.

Executive Director
Global In Vitro Toxicology
Charles River Laboratories
Cleveland, OH

Neil Carragher
Neil CarragherPresident-Elect

Neil Carragher is Professor of Drug Discovery at the University of Edinburgh, he graduated from the University of Aberdeen, Scotland UK in 1992 with a B.Sc Honours degree in the subject of “Cell and Immunobiology”.  He then took up a position within industry at the Yamanouchi Research Institute, Oxford, England UK where he also gained his PhD. He then held consecutive postdoctoral positions within the Department of Pathology, University of Washington, Seattle, USA and at the Beatson Institute for Cancer Research, Glasgow, Scotland UK. In 2004 Neil returned to the pharmaceutical industry as Principal Scientist with the Advanced Science and Technology Laboratory at AstraZeneca where he pioneered early multiparametric high-content phenotypic screening approaches. In 2010 he once again made the career switch from industry to academia and took up the post of Principal Investigator of Drug Discovery at the University of Edinburgh where he leads a research group and is currently co-director of the Edinburgh Cancer Discovery Unit and the Edinburgh Phenotypic Assay Centre. Primary research interests include advancing High-content analysis, phenotypic screening, Reverse Phase Protein Array technology, drug combinations and cancer drug discovery. Neil is also Chief Scientific Officer of the Phenomics Discovery initiative, a public-private consortia to advance phenotypic screening technologies https://npsc.ac.uk/pdi and is a founding member of the European Cell Based Assay Interest group www.eucai.org and global RPPA society.

Ann F. Hoffman
Ann F. HoffmanPast President

Ann is the current Past President of the society (2019 to 2020). She has been a pivotal member of the council and society for several years and is currently an investigator at GSK involved in High Content Imaging and Drug Design and Selection.

2021 Scientific Program Chairs

Neil Carragher
Neil Carragher
Heba Sailem
Heba Sailem
Santosh Hariharan
Santosh Hariharan
Nicholas M. Radio
Nicholas M. Radio

Council

Shannon Mumenthaler
University of Southern California

Shannon Mumenthaler, PhD, is an Assistant Professor of Medicine and Biomedical Engineering at the University of Southern California. She is also the Laboratory Director for the Ellison Institute, which is a translational institute that bridges research and innovation by bringing together researchers, patients, and physicians dedicated to improving human health. Although Dr. Mumenthaler’s primary scientific training is in cell biology, she applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians and engineers to explore critical areas in cancer. Her overall research interest focuses on the importance of the tumor microenvironment in influencing tumor progression and treatment response. She is developing physiologically-relevant model systems that capture the microenvironmental context of a tumor and coupling these preclinical models with microscopy-based imaging pipelines to provide deeper insights into the evolving tumor.

Heba Sailem
University of Oxford

Heba is a Sir Henry Wellcome Research Fellow at the Institute of Biomedical Engineering at the University of Oxford. Before joining Oxford, she obtained her PhD at the Institute of Cancer Research in London with Prof Chris Bakal. She has extensive expertise in biomedical imaging and high throughput screening. Her focus is on developing machine learning approaches for automated and comprehensive analysis of large-scale genetic and drug screening datasets. For example, she developed KCML to predict gene functions based on phenotypic screens based on siRNA and CRISPR screens.  She has also developed several new image analysis and deep learning algorithms. These include a profiling of vascular network  morphology and single cell detection in wound healing assays.

She is an active member of the Early Career Section committee at the Royal Microscopy Society where she participated in setting up the committee and promoting ECR in microscopy career progression.

David L. Becker
The Exeter Group

David is president of The Exeter Group, a life-sciences commercialization consultancy he founded in 1992. Seconded from Exeter, Dr. Becker recently served as Commercial Lead at ExpressCells, a genetic engineering start-up focused on producing custom cell lines for drug discovery, toxicology, and other biologic research. Prior to joining ExpressCells, he was managing director of Catalysis Partners, providing strategic solutions in drug development and commercialization to small life sciences companies. He is a board-certified internist.

Todd Shelper
Griffith University

Todd Shelper is a research fellow at the Menzies Health Institute Queensland, working on cell-based therapies for The Spinal Injury Project. He obtained his PhD from Griffith University in 2014 with his project focusing on the development of more physiologically relevant in vitro 3D pancreatic cancer models for use in anti-cancer drug discovery programs. During his time at Griffith University, he has worked on commercial anti-infective high throughput screening and lead optimisation projects. He is actively involved in developing primarily imaging-based assays and has run numerous HTS and HCS campaigns across a range of biology including oncology and parasitology. Todd is currently investigating the therapeutic potential of transplanting olfactory glia in pre-clinical spinal injury models. He has been a board member with the society for 3 years and participated in educational seminars and event planning at the annual SBI2 meetings.

Don Apanovitch
Ferring Pharmaceuticals

Over the past 24 years Don has worked at multiple major pharmaceutical companies involved in early stage research with a focus on use and application of high content imaging (HCI) to drive and support target-based drug discovery programs. Most recently, as the director of Functional Genomics for the Pfizer Oncology Integrative Biotechnology (IBT) Group , he implemented HCI for target identification in early stage drug discovery, for in vitro and in situ functional and phenotypic characterization, as well as for providing technical and strategic guidance for new assays and innovative applications for all oncology programs moving towards IND filing. Additionally, he initiated application of both machine learning and AI technology to help validate and screen images for repurposing of HCI data for drug screening applications.

James Finley
Pfizer

Jim is a Principal Scientist in the Global Pathology and Investigative Toxicology group in Drug Safety R&D at Pfizer where he has been since 2000. Since receiving his BSc in Biology from Old Dominion University in 1986, he has worked 10 years in academic research (University of Virginia) and 20+ years in biopharma research (Pfizer, Wyeth) in a wide variety of research fields including neuroscience, deafness, cardiovascular/metabolic diseases, and oncology. The Investigative Tox group is a small team that does deep dive investigations into specific toxicity issues and builds safety de-risking models for programs across all therapeutic areas. As the imaging technical expert, he specializes in imaging-based assays for target identification/evaluation, drug activity/biodistribution/cell viability/toxicity. He has expertise in all phases of histotechnology (cell/tissue processing, sectioning, staining, immunohistochemistry); microscopy (fluorescence, confocal, live cell, multidimensional, 3D, HCS); in vitro assays (intracellular trafficking, endocytosis, angiogenesis, ROS, wound healing, NETosis, transfection, knockdown); and image analysis on cells or tissue using multiple platforms. His recent work has focused heavily on building 3D organoid and multi-physiological-system (MPS) models for safety and tox endpoints. He has been a member of SBI2 since 2015 and find it to be an invaluable resource for networking and keeping up with the latest HCS advances and technology.

Beth Cimini
Broad Institute

Dr. Beth Cimini is the Lead Image Assay Developer for the Imaging Platform at the Broad Institute in Cambridge, MA.  After doing research in visual neuroscience with Dr. William Eldred at Boston University as an undergraduate, she obtained a PhD in Biochemistry and Molecular Biology with Dr. Elizabeth Blackburn at UCSF, studying the difference between splicing variants of the telomere master scaffolding protein TIN2.  These projects honed her interests in image analysis, leading her to join Dr. Anne Carpenter's lab at the Broad, where she leads a team collaborating with approximately 30 outside scientists per year on their own custom image analysis projects.  She also co-maintains the lab's main software tool, CellProfiler, and directs the Broad efforts towards community engagement and driving biological projects for the Center for Open Bioimage Analysis (COBA).

Santosh Hariharan
Pfizer

Santosh is currently working as a principal scientist at Pfizer where he is leading compound profiling efforts using cell painting assay. Santosh also has over 9 years of academic and industry experience in high content imaging and analysis field. His experience spans applying HCA in field of protein trafficking, oncology and fibrosis. While working as a scientist at Sanford-Burnham Medical Research Institute (SBMRI), he developed several high content screening assays and was in-charge of assisting biologist with their imaging and analysis protocols. He completed his PhD from University of Toronto in Canada. During his graduate work, he developed several image-analysis pipelines to computationally predict protein localization and quantify associated dynamics. He has also developed image analysis algorithms for fast analysis of 3D organoid images.

Ty Voss
National Institutes of Health

Ty Voss was a founding member of the National Cancer Institute’s High-Throughput Imaging Facility and served there as head. He then worked as senior applications scientist for the PerkinElmer High-Content Analysis Instrumentation Sales Team. Currently, he assists researchers at the National Center for Advancing Translational Sciences with cell-based assay development and customized automated image analysis.

Nicholas M. Radio
Thermo Fisher Scientific

Nicholas (Nick) Radio is the Global Product Manager for High-Content Screening (HCS) at Thermo Fisher Scientific.  Nick holds a Ph.D. in Pharmacology-Toxicology and an MBA with focus in Strategic Management.  He has authored over 25 publications, including two invited book chapters on utilizing HCS for the study of neurotoxicity.  Nick has over 15 years of industry experience in HCS across roles in research and development, field applications, and technical product specialties.

Sheila Kantesaria
Pfizer

Sheila is a Senior Scientist in the Primary Pharmacology Group at Pfizer in Groton, CT.  Her current work focuses on high content imaging assay development and screening in various cell-based and physiologically relevant systems.  She haS experience with spheroid, MPCC, and organ-on-a-chip models. Overall, she has 20 years of experience in cell-based and biochemical assay development spanning from early stages of drug discovery to developing assays for de-risking compound toxicity. She obtained my B.S.  from the Rochester Institute of Technology and Masters (BA in Biology) from Brown University

Committees 

Conference Planning Committee

Judi Wardwell-Swanson
Debra Nickischer
Jeff Haskins

Scientific Sessions
and Keynote Speakers

Neil Carragher
Beth Cimini
Nicholas M. Radio
Heba Sailem

Poster Session

Shannon Mumenthaler
Nicholas M. Radio
James Finley
Neil Carragher

Exhibits

Judi Wardwell-Swanson
Santosh Hariharan
James Finley

Education

Beth Cimini
Don Apanovitch
Sheila Kantesaria
Shannon Mumenthaler

Marketing / Social Media

Judi Wardwell-Swanson
Santosh Hariharan
David L. Becker
James Finley

Todd Shelper
David L. Becker
Ty Voss
Seungil Kim

Membership

Neil Carragher
Sheila Kantesaria
James Finley

Ann F. Hoffman
Ty Voss
Justin D. Boyd